Advances in iPSC technology and in vivo reprogramming are expanding the possibilities for cell therapy. Explore the science ...

As cell therapy advances toward clinical reality, iPSC-derived cellular products, in vivo reprogramming strategies, and ...

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Cellistic®, a pioneer in iPSC-based off-the-shelf cell therapy development and manufacturing, announces the successful audit and GMP certification of its ...

iPSCore platform delivered over 500 characterized iPSC lines during first year of collaboration SAN DIEGO, March 11, 2026--(BUSINESS WIRE)--iXCells Biotechnologies USA, Inc. ("iXCells"), a leading ...

PHILADELPHIA--(BUSINESS WIRE)--Accelerated Biosciences and Stemmatters are thrilled to announce their strategic partnership aimed at co-developing and co-marketing human induced pluripotent stem cells ...

iXCells Biotechnologies USA, announced the delivery of over 500 characterized induced pluripotent stem cell (iPSC) lines as part of a multi-year collaboration with a global biotechnology company. The ...

Avoiding many of the pitfalls associated with conventional iPSC reprogramming methods that can introduce genetic instability, PSXi013 has been reprogrammed using our state-of-the-art, footprint-free ...

Scientists at the Centre for Genomic Regulation (CRG) and other institutions have published details of a treatment that accelerates the production of female induced pluripotent stem cells (iPSCs) from ...

XCells Biotechnologies ("iXCells"), a leading provider of human cell-based solutions and custom iPSC services, today ...